AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02900001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early coronary angiography
Description: Routine coronary angiography and revascularization if appropriate within 24 hours
Study NCT02900001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed coronary angiography
Description: Routine coronary angiography and revascularization if appropriate after 72 hours
Study NCT01417182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFBC
Description: A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
Study NCT04213521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory balance exercise
Description: Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.
Study NCT04213521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balance exercise
Description: such as static and dynamic standing balance without altered sensory inputs.
Study NCT04213521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional balance exercise
Description: such as static and dynamic standing balance without altered sensory inputs.
Study NCT02410733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipo-MERIT
Description: vaccination
Study NCT01957527 — intervention group
Intervention type: DEVICE
Intervention: Peripheral arterial tonometry (EndoPAT)
Study NCT04443751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1702
Description: SHR-1702 monotherapy, administered IV
Study NCT00555204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: 35 mg - capsules once daily for 12 weeks
Study NCT00555204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - capsules once daily for 12 weeks
Study NCT03024320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M2M
Description: An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic \& 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic \& 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).
Study NCT03024320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Telecoaching on health-based topics, not including physical activity.
Study NCT05180747 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Frequency of physical therapy sessions
Description: Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
Study NCT00413608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel
Study NCT02373462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Study NCT02373462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other anti-hypertensive drug
Description: CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
Study NCT03141853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-assisted Therapy
Description: Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
Study NCT03141853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arthritis Exercise Education
Description: Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
Study NCT02740257 — intervention group
Intervention type: OTHER
Intervention: Photos
Description: Photos will be taken of skin lesion markings using a smart phone or tablet
Study NCT03161197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
Study NCT03456544 — intervention group
Intervention type: DRUG
Intervention: Vancomycin
Description: Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
Study NCT01710696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol
Description: 5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
Study NCT01710696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol
Description: 0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
Study NCT01676064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ringer lactate solution
Study NCT01676064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restrictive fluid regime
Study NCT02845336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 100mg PO twice per day for 3 months
Study NCT02845336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artificial tears
Description: Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
Study NCT02845336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artificial tears
Description: Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
Study NCT00348517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Free Lubricant Eye Drops
Description: 1-2 drops per eye four times per day for 42 days
Study NCT00348517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Liquigel Lubricant Eye Drops
Description: 1-2 drops per eye four times per day for 42 days
Study NCT02324452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (capecitabine or 5-fluorouracil)
Description: Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
Study NCT01839539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic and cytokine-induced killer cells
Study NCT04418167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSI-1187
Description: JSI-1187 capsules for oral administration
Study NCT04418167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib capsules for oral administration
Study NCT03651336 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ARGOS-IO Sensor Pressure System
Description: The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
Study NCT02226250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 Placebo Beverages
Description: Sugar beverage 2 hr before meal, with meal and 2 hr after meal
Study NCT04567329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: 100% perfluorohexyloctane
Study NCT04567329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 0.6% sodium chloride solution
Study NCT06563219 — intervention group
Intervention type: OTHER
Intervention: Glasgow coma scale
Description: The levels of response in the components of the Glasgow Coma Scale are 'scored' from 1, for no response, up to normal values of 4 (Eye-opening response) 5 ( Verbal response) and 6 (Motor response) The total Coma Score thus has values between three and 15, three being the worst and 15 being the highest.
Study NCT06563219 — intervention group
Intervention type: OTHER
Intervention: Hunt-Hess scale
Description: The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5:~* Grade 1: Asymptomatic or minimal headache, slight neck stiffness.~* Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy.~* Grade 3: Drowsiness, confusion, or a mild focal deficit.~* Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance.~* Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance.
Study NCT06563219 — intervention group
Intervention type: OTHER
Intervention: World Federation of Neurological Surgeons (WFNS) scale
Description: The World Federation of Neurological Surgeons (WFNS) scale, introduced in 1988, is used to evaluate the clinical severity of patients with SAH. This scale is derived from the GCS score and considers the presence of motor deficits:~* Grade 1: GCS score of 15, no motor deficit~* Grade 2: GCS score of 13 to 14, no motor deficit~* Grade 3: GCS score of 13 to 14, with motor deficit~* Grade 4: GCS score of 7 to 12, with or without motor deficit~* Grade 5: GCS score of 3 to 6, with or without motor deficit
Study NCT06563219 — intervention group
Intervention type: OTHER
Intervention: modified Fisher scale
Description: The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed:~* Grade 0: No hemorrhage apparent in CT.~* Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH).~* Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH.~* Grade 3: Thick (> 1 mm) hemorrhage without bilateral IVH.~* Grade 4: Thick (> 1 mm) hemorrhage with bilateral IVH.
Study NCT06563219 — intervention group
Intervention type: OTHER
Intervention: VASOGRADE scale
Description: The VASOGRADE scale was established to estimate the risk of delayed cerebral ischemia following SAH. This scale is based on the WFNS and the modified Fisher scales at admission. There are three categories:~* Green: WFNS score of 1 or 2 and modified Fisher scale of 1 or 2.~* Yellow: WFNS score of 1 or 3 and modified Fisher scale of 3 or 4.~* Red: WFNS score of 4 or 5 and any modified Fisher scale score.
Study NCT06563219 — intervention group
Intervention type: OTHER
Intervention: Ogilvy and Carter scale
Description: The Ogilvy and Carter scale is a grading system used to predict the outcomes of surgical treatment in patients with SAH due to a ruptured aneurysm. The scale considers multiple factors, including age, Hunt and Hess grade, Fisher grade, and aneurysm size, with a score assigned to each of these variables:~* Age greater than 50~* Hunt and Hess grade of 4 to 5~* Fisher grade scores of 3 to 4~* Aneurysm size >10 mm~* An additional point is added for a giant posterior circulation aneurysm (≥25 mm)
Study NCT01316146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.CD30 T cells
Description: Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc.
Study NCT03133143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognifit
Description: CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.
Study NCT03133143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIMS 4 (Maxis, Inc)
Description: The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
Study NCT01167270 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Child Safety Insights
Description: A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
Study NCT01167270 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Insights
Description: Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
Study NCT01756885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
Study NCT01756885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
Study NCT01756885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
Study NCT01756885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial.
Study NCT01756885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial.
Study NCT00627796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide-Autogel 120 mg
Description: ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were \< 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels \<1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
Study NCT03068780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Description: 10% birch bark extract in 90% sunflower oil
Study NCT03068780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control gel
Description: Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
Study NCT03472196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoZip System
Description: The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight.
Study NCT00858780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg etanercept once weekly + methotrexate
Study NCT00858780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 25mg etanercept once weekly + methotrexate
Study NCT00858780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator once weekly + methotrexate
Study NCT01426360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control dentifrice
Description: use the dentifrice to brush teeth twice a day for one minute for 3 days
Study NCT01426360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strontium chloride/potassium nitrate dentifrice
Description: use the dentifrice to brush teeth twice daily for 3 days
Study NCT01988636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
Study NCT01988636 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
Study NCT01988636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01011855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
Study NCT01011855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
Study NCT01011855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
Study NCT01011855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
Study NCT01011855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEHC IWS 4400 & Giraffe warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.